Analysis of pharmacogenetic traits in two distinct South African populations

Human Genomics

Volumn 5, Issue 4, 2011, Pages 265-282

  Ikediobi, Ogechi ^a   Aouizerat, Bradley ^a   Xiao, Yuanyuan ^b   Gandhi, Monica ^b   Gebhardt, Stefan ^c   Warnich, Louise ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

Antiretrovirals; Cape Mixed Ancestry; HIV; Pharmacogenetics; South Africa; Xhosa

Indexed keywords

ABCB1 PROTEIN, HUMAN; BILIRUBIN URIDINE DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; BILIRUBIN URIDINE-DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; BONE DENSITY CONSERVATION AGENT; CYP2C18 PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P 450 CYP3A45; CYTOCHROME P-450 CYP3A45; CYTOCHROME P450; CYTOCHROME P450 3A; CYTOCHROME P450 CYP2A7; GLUCURONOSYLTRANSFERASE; GLYCOPROTEIN P; PHARMACOLOGICAL BIOMARKER; UNSPECIFIC MONOOXYGENASE;

ADULT; ARTICLE; COMPARATIVE STUDY; FEMALE; GENE FREQUENCY; GENETIC MARKER; GENETICS; HAPLOTYPE; HUMAN; MALE; NEGRO; PHARMACOGENETICS; POPULATION; SINGLE NUCLEOTIDE POLYMORPHISM; SOUTH AFRICA;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ARYL HYDROCARBON HYDROXYLASES; BIOMARKERS, PHARMACOLOGICAL; BONE DENSITY CONSERVATION AGENTS; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENE FREQUENCY; GENETIC MARKERS; GLUCURONOSYLTRANSFERASE; HAPLOTYPES; HUMANS; MALE; P-GLYCOPROTEIN; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; POPULATION; SOUTH AFRICA; YOUNG ADULT;

EID: 80054025177     PISSN: 14739542     EISSN: 14797364     Source Type: Journal    
DOI: 10.1186/1479-7364-5-4-265     Document Type: Article

References (27)

1. Ikediobi, O.N., Shin, J., Nussbaum, R.L., Phillips, K.A. et al. (2009), 'Addressing the challenges of the clinical application of pharmacogenetic testing', Clin. Pharmacol. Ther. Vol. 86, pp. 28-31.
2. Marques, S.C. and Ikediobi, O.N. (2010), 'The clinical application of UGT1A1 pharmacogenetic testing: Gene-environment interactions', Hum. Genomics Vol. 4, pp. 238-249.
3. Tishkoff, S.A., Reed, F.A., Friedlaender, F.R., Ehret, C. et al. (2009), 'The genetic structure and history of Africans and African Americans', Science Vol. 324, pp. 1035-1044.
4. Yen-Revollo, J.L., van Booven, D.J., Peters, E.J., Hoskins, J.M. et al. (2009), 'Influence of ethnicity on pharmacogenetic variation in the Ghanaian population', Pharmacogenomics J. Vol. 9, pp. 373-379.
5. Drögemö ller, B.I., Wright, G.E.B., Niehaus, D.J.H., Koen, L. et al. (2010), 'Characterization of the genetic profile of CYP2C19 in two South African populations', Pharmacogenomics Vol. 11, pp. 1095-1103.
6. Miller, S.A., Dykes, D.D. and Polesky, H.F. (1988), 'A simple salting out procedure for extracting DNA from human nucleated cells', Nucleic Acids Res. Vol.16, p. 1215.
7. Parathyras, J., Gebhardt, S., Hillermann-Rebello, R., Grobbelaar, N. et al. (2009), 'A pharmacogenetic study of CD4 recovery in response to HIV antiretroviral therapy in two South African population groups', J. Hum. Genet. Vol. 54, pp. 261-265.
8. Edlund, C.K., Lee, W.H., Li, D., van den Berg, D.J. et al. (2008), 'Snagger: A user-friendly program for incorporating additional information for tagSNP selection', BMC Bioinformatics Vol. 9, p. 174.
9. Mathias, R.A., Gao, P., Goldstein, J.L., Wilson, A.F. et al. (2006), 'A graphical assessment of p-values from sliding window haplotype tests of association to identify asthma susceptibility loci on chromosome 11q', BMC Genet. Vol. 7, p. 38.
10. The Joint United Nations Programme on HIV/AIDS, http://www. unaids.org (last accessed 30th April, 2011).
11. Haas, D.W., Bartlett, J.A., Andersen, J.W., Sanne, I. et al. (2006), 'Pharmacogenetics of nevirapine-associated hepatotoxicity: An Adult AIDS Clinical Trials Group collaboration', Clin. Infect. Dis. Vol. 43, pp. 783-786.
12. Ritchie, M.D., Haas, D.W., Motsinger, A.A., Donahue, J.P. et al. (2006), 'Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity', Clin. Infect. Dis. Vol. 43, pp. 779-782.
13. Zhang, Y.T., Yang, L.P., Shao, H., Li, K.X. et al. (2008), 'ABCB1 polymorphisms may have a minor effect on ciclosporin blood concentrations in myasthenia gravis patients', Br. J. Clin. Pharmacol. Vol. 66, pp. 240-246.
14. South African Department of Health website. http://www.doh.gov.za (last accessed 30th April, 2011).
15. Mahungu, T.W., Johnson, M.A., Owen, A. and Back, D.J. (2009), 'The impact of pharmacogenetics on HIV therapy', Int. J. STD AIDS Vol. 20, pp. 145-151.
16. Bertrand, J., Treluyer, J.M., Panhard, X., Tran, A. et al. (2009), 'Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART', Eur. J. Clin. Pharmacol. Vol. 65, pp. 667-678.
17. Anderson, P.L., Lamba, J., Aquilante, C.L., Schuetz, E. et al. (2006), 'Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: A pilot study', J. Acquir. Immune Defic. Syndr. Vol. 42, pp. 441-449.
18. Kuehl, P., Zhang, J., Lin, Y., Lamba, J. et al. (2001), 'Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression', Nat. Genet. Vol. 27, pp. 383-391.
19. Balram, C., Zhou, Q., Cheung, Y.B. and Lee, E.J. (2003), 'CYP3A5*3 and *6 single nucleotide polymorphisms in three distinct Asian populations', Eur. J. Clin. Pharmacol. Vol. 59, pp. 123-126.
20. Sanna, S., Busonero, F., Maschio, A., McArdle, P.F. et al. (2009), 'Common variants in the SLCO1B3 locus are associated with bilirubin levels and unconjugated hyperbilirubinemia', Hum. Mol. Genet. Vol. 18, pp. 2711-2718.
21. Innocenti, F., Grimsley, C., Das, S., Ramírez, J. et al. (2002), 'Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups', Pharmacogenetics Vol.12, pp. 725-733.
22. Mehlotra, R.K., Bockarie, M.J. and Zimmerman, P.A. (2007) 'CYP2B6 983T.C polymorphism is prevalent in West Africa but absent in Papua New Guinea: Implications for HIV/AIDS treatment', Br. J. Clin. Pharmacol. Vol. 64, pp. 391-395.
23. Klein, T.E., Chang, J.T., Cho, M.K., Easton, K.L. et al. (2001), 'Integrating genotype and phenotype information: An overview of the PharmGKB Project', Pharmacogenomics J. Vol. 1, pp. 167-170.
24. Klein, K., Lang, T., Saussele, T., Barbosa-Sicard, E. et al. (2005), 'Genetic variability of CYP2B6 in populations of African and Asian origin: Allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz', Pharmacogenet. Genomics Vol. 15, pp. 861-873.
25. Wang, J., Sönnerborg, A., Rane, A., Josephson, F. et al. (2006), 'Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz', Pharmacogenet. Genomics Vol. 16, pp. 191-198.
26. Ciccacci, C., Borgiani, P., Ceffa, S., Sirianni, E. et al. (2010), 'Nevirapine-induced hepatotoxicity and pharmacogenetics: A retrospective study in a population from Mozambique', Pharmacogenomics Vol. 11, pp. 23-31.
27. Wright, G.E.B., Niehaus, D.J.H., Drögemöller, B.I., Koen, L. et al. (2010), 'Elucidation of CYP2D6 genetic variants in a unique African population: Implications for the future application of pharmacogenetics in the Xhosa population', Ann. Hum. Genet. Vol. 74, pp. 340-350.